Phase II/III induction study of AJG501 in patients with active ulcerative colitis
Phase 2
- Conditions
- lcerative colitis
- Registration Number
- JPRN-jRCT2080221110
- Lead Sponsor
- Ajinomoto Pharmaceuticals Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Baseline Revised Sutherland DAI score of 4-8 including abnormal rectal bleeding score
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in Revised Sutherland DAI<br>Revised Sutherland DAI
- Secondary Outcome Measures
Name Time Method